Advertisement

 

 

Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.

Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.
Author Information (click to view)

Lomonosova E, Zlotnick A, Tavis JE,


Lomonosova E, Zlotnick A, Tavis JE, (click to view)

Lomonosova E, Zlotnick A, Tavis JE,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Antimicrobial agents and chemotherapy 2017 02 2361(3) pii 10.1128/AAC.02441-16

Abstract

Combination therapies are standard for management of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections; however, no such therapies are established for human hepatitis B virus (HBV). Recently, we identified several promising inhibitors of HBV RNase H (here simply RNase H) activity that have significant activity against viral replication in vitro Here, we investigated the in vitro antiviral efficacy of combinations of two RNase H inhibitors with the current anti-HBV drug nucleoside analog lamivudine, with HAP12, an experimental core protein allosteric modulator, and with each other. Anti-HBV activities of the compounds were tested in a HepG2-derived cell line by monitoring intracellular core particle DNA levels, and cytotoxicity was assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The antiviral efficiencies of the drug combinations were evaluated using the median-effect equation derived from the mass-action law principle and combination index theorem of Chou and Talalay. We found that combinations of two RNase H inhibitors from different chemical classes were synergistic with lamivudine against HBV DNA synthesis. Significant synergism was also observed for the combination of the two RNase H inhibitors. Combinations of RNase H inhibitors with HAP12 had additive antiviral effects. Enhanced cytotoxicity was not observed in the combination experiments. Because of these synergistic and additive effects, the antiviral activity of combinations of RNase H inhibitors with drugs that act by two different mechanisms and with each other can be achieved by administering the compounds in combination at doses below the respective single drug doses.

Submit a Comment

Your email address will not be published. Required fields are marked *

nine − nine =

[ HIDE/SHOW ]